Literature DB >> 22919182

Comments: Other considerations about surgery in lung cancer.

Mostafa Ghanei1, Amin Saburi, Jamal Akhavan-Moghadam.   

Abstract

Entities:  

Year:  2012        PMID: 22919182      PMCID: PMC3424882     

Source DB:  PubMed          Journal:  Lung India        ISSN: 0970-2113


× No keyword cloud information.
Sir, I read with great interest a recently published article on beneficial aspects of surgery in small cell lung cancer.[1] Prof. Koul skillfully concluded about the therapeutic role of surgery in patients affected by limited-stage of lung cancer (LC) in terms of histopathologic characteristics (small cell or non-cell LC) and staging. Regardless of the discussed subjects, it seems that if a few points are also considered, it will be helpful especially for further studies. Surgery was usually recommended for limited stage of cancer and a proposed treatment for advanced stages of disease (regardless of the type of pathologic findings) is chemotherapy combined with radiotherapy, although up to about 33% increase in 5-year survival in response to the chemotherapy is expected in patients with limited stage of LC.[2] But there are some newly recognized advantages for surgery even in advanced cancerous lesions. Alpha-N-acetylgalactosaminidase (anagalase) is an important enzyme, which deglycosylates and therefore inactivates human group-specific component (Gc) protein, a well-known vitamin D-binding protein (DBP) or Gc globulin, which has vital role in activation of macrophage to enhance humoral and cellular immune system but some infected cells (e.g., cells infected by HIV) or cancerous cells produce this enzyme and protect themselves against activated macrophages.[3] Hence, total resection or debulkation can reduce amount of this enzyme and can be helpful in every stage theorically.[4] On the other hand, we have to consider age as a restricting factor in surgery (especially along with additional disabilities), although it has been shown that surgery in older patients with LC can be a beneficial and safe procedure.[5] Recently, minimal invasive surgery was extended in treatment of LC although it has a significant limitation in more internal lesions.[6] There are some recent developments in immune-based chemotherapy but surgery remains as a principle of LC treatment. Further investigations in the role and methods of surgery in patients with higher stage LC are needed because the majority of patients are diagnosed in advanced stages of the LC.[7]
  7 in total

Review 1.  Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity.

Authors:  Hideko Nagasawa; Yoshihiro Uto; Hideyuki Sasaki; Natsuko Okamura; Aya Murakami; Shinichi Kubo; Kenneth L Kirk; Hitoshi Hori
Journal:  Anticancer Res       Date:  2005 Nov-Dec       Impact factor: 2.480

Review 2.  Pulmonary resection in the elderly.

Authors:  Maria D Castillo; Paul M Heerdt
Journal:  Curr Opin Anaesthesiol       Date:  2007-02       Impact factor: 2.706

Review 3.  Management of non-small-cell lung cancer in the older adult.

Authors:  Ari VanderWalde; Sumanta Kumar Pal; Karen L Reckamp
Journal:  Maturitas       Date:  2011-02-03       Impact factor: 4.342

4.  Clinico-pathological profile of lung cancer in Uttarakhand.

Authors:  Jagdish Rawat; Girish Sindhwani; Dushyant Gaur; Ruchi Dua; Sunil Saini
Journal:  Lung India       Date:  2009-07

Review 5.  New approaches for small-cell lung cancer: local treatments.

Authors:  Wilfried Eberhardt; Sonke Korfee
Journal:  Cancer Control       Date:  2003 Jul-Aug       Impact factor: 3.302

6.  Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).

Authors:  Nobuto Yamamoto; Hirofumi Suyama; Nobuyuki Yamamoto; Naofumi Ushijima
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

7.  Surgery in limited-disease small-cell lung cancer.

Authors:  Parvaiz A Koul
Journal:  Lung India       Date:  2012-01
  7 in total
  1 in total

1.  Authors' reply.

Authors:  Parvaiz A Koul
Journal:  Lung India       Date:  2012-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.